



Proteomics International

LABORATORIES LTD

ASX/Media Release

22 November 2017

ASX code: PIQ

Proteomics International strengthens Board and Business Development team

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a leader in predictive diagnostics and analytical services, is pleased to announce the appointment of a new Board member along with engagement of two industry experts to promote business expansion and product commercialisation.

- **New appointments target business growth and commercialisation of PromarkerD, the company's world leading predictive diagnostic test for diabetic kidney disease**
- **Add further multi-national experience to the Board and Business Development team**
- **Bring proven track records in diagnostic test licensing and revenue growth**
- **Deepens Proteomics International's ability to target its key markets of the USA, Japan and India**

Mr Paul House, Proteomics International - Non-Executive Director

Mr House will become a Non-Executive Director, effective immediately, and brings a wealth of commercial and management experience from working with multi-national corporations over the last 25 years.

Paul House has recently returned to Australia after eight years serving as Managing Director, SGS India, where he was responsible for a workforce of approximately 4,500 personnel across 65 locations in India, including 38 laboratories. SGS is the world's leading Testing, Inspection and Certification (TIC) company, and operates a network of offices and laboratories in more than 140 countries. Mr House has also previously held Chief Financial Officer and COO roles, and was Senior Manager for several years at a leading global management consultancy firm.

Mr House has a track record for delivery of business performance targets, revenue growth, margin improvement, market share and productivity, across multiple services, markets and borders. He will work with the Board and Mr Chuck Morrison, Proteomics International's US-based Head of Business Development, to find business expansion opportunities and develop strategic alliances across the company's activities.

Mr Eric Button, NeoMark Ventures, USA - Consultant

The addition to the Board follows the engagement of Mr Eric Button, the president of NeoMark Ventures, Inc, a consulting and investment firm specialising in the development and commercialisation of emerging diagnostic technologies.

For the past 20 years, Mr Button has been at the forefront of new diagnostics product development, including the commercialisation of three novel diabetes tests.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

As Senior Vice President of Diagnostics at Metabolon, Mr Button introduced Quantose IR and Quantose IGT for the diagnosis of prediabetes. Prior to that, as the founder and President of GlycoMark Inc., Mr Button directed the foundational scientific studies and the intellectual property, regulatory, and commercialisation/partnering strategies for the first, novel FDA-cleared diabetes test introduced in the US in the past 20 years.

Eric Button has previously established partnerships with several of the world's leading diagnostic laboratories, as well as a multitude of specialised/smaller labs. Eric Button's role for Proteomics International is focused on commercialising PromarkerD, the company's world leading predictive test for diabetic kidney disease, in the vibrant US market for specialist laboratory testing (so-called Laboratory Developed Tests that are run by certified laboratories). Mr Button has already identified several commercialisation prospects for the company which are being pursued.

Dr. Masafumi Yoshimoto, PhamaBDL, Japan - Consultant

Separately, in Japan, Proteomics International has engaged Dr. Masafumi Yoshimoto of PhamaBDL LLC, another career executive of the diagnostics and pharma industry, to pursue business development and licensing (BDL) opportunities.

Dr. Yoshimoto worked for nearly 40 years with Sankyo (now Daiichi-Sankyo, the second largest pharmaceutical company in Japan), where he was involved in hundreds of deals in R&D alliances, in-licensing and out-licensing. Dr. Yoshimoto is working closely with Proteomics International's Director, Mr Roger Moore (formerly of Senior Vice President Novo Nordisk, Japan and Oceania) to commercialise PromarkerD in Japan.

Commenting on the new appointments, Dr Richard Lipscombe, Proteomics International's Managing Director said "We are extremely pleased to have these world class executives on board – it adds strength and depth to our management team which will help us as we expand our business and commercialise the PromarkerD test in key markets around the world."

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The company's business model harnesses its proprietary technology platform to work across three integrated areas, each massive growth markets:

1. Diagnostics: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.

By 2020 the biomarkers market is estimated to double in size to \$45.6 billion, and the personalised medicine market is forecast to be worth over \$149 billion.

2. Analytical services: Specialist contract research – focus on biosimilars QC and pharmacokinetic testing for clinical trials.

The global biosimilars market is expected to reach \$10.5 billion by 2022, having surpassed \$3.3 billion in 2016 as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.

3. Drug discovery: Therapeutic peptide drug discovery - focus on painkillers and antibiotics.

The global peptide therapeutics market is currently estimated to be worth \$18 billion with a chronic need to find new drugs to combat bacterial infections.